BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 38100920)

  • 1. TTF-1 status in early-stage lung adenocarcinoma is an independent predictor of relapse and survival superior to tumor grading.
    Schallenberg S; Dernbach G; Dragomir MP; Schlachtenberger G; Boschung K; Friedrich C; Standvoss K; Ruff L; Anders P; Grohé C; Randerath W; Merkelbach-Bruse S; Quaas A; Heldwein M; Keilholz U; Hekmat JK; Rückert C; Büttner R; Horst D; Klauschen F; Frost N
    Eur J Cancer; 2024 Jan; 197():113474. PubMed ID: 38100920
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic impact of TTF-1 expression in patients with stage IV lung adenocarcinomas.
    Schilsky JB; Ni A; Ahn L; Datta S; Travis WD; Kris MG; Chaft JE; Rekhtman N; Hellmann MD
    Lung Cancer; 2017 Jun; 108():205-211. PubMed ID: 28625636
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The prognostic role of thyroid transcription factor-1 in lung adenocarcinoma.
    Oktay E; Oflazoglu U; Varol Y; Tanriverdi O; Mermur N; Arda HU; Demir L; Keskin O; Ahmadli T; Somali I; Oztop I; Meydan N
    J Cancer Res Ther; 2018 Dec; 14(Supplement):S1201-S1208. PubMed ID: 30539871
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The role of Thyroid Transcription Factor-1 and Tumor differentiation in Resected Lung Adenocarcinoma.
    Huang TW; Lin KF; Lee CH; Chang H; Lee SC; Shieh YS
    Sci Rep; 2017 Oct; 7(1):14222. PubMed ID: 29079814
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The prognostic role of thyroid transcription factor-1 in lung adenocarcinoma.
    Oktay E; Oflazoglu U; Varol Y; Tanriverdi O; Mermur N; Arda HU; Demir L; Keskin O; Ahmadli T; Somali I; Oztop I; Meydan N
    J Cancer Res Ther; 2020; 16(4):737-744. PubMed ID: 32930112
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Thyroid transcription factor-1 as a prognostic indicator for stage IV lung adenocarcinoma with and without EGFR-sensitizing mutations.
    Park JY; Jang SH; Kim HI; Kim JH; Park S; Hwang YI; Jung KS; Seo J; Lee CY; Ko Y; Park YB
    BMC Cancer; 2019 Jun; 19(1):574. PubMed ID: 31196060
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Who benefit from adjuvant chemotherapy in stage I lung adenocarcinoma? A multi-dimensional model for candidate selection.
    Jiang MQ; Qian LQ; Shen YJ; Fu YY; Feng W; Ding ZP; Han YC; Fu XL
    Neoplasia; 2024 Apr; 50():100979. PubMed ID: 38387107
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The IASLC Proposed Grading System Accurately Predicts Prognosis and Mediastinal Nodal Metastasis in Patients With Clinical Stage I Lung Adenocarcinoma.
    Xu L; Su H; Hou L; Wang F; Xie H; She Y; Gao J; Zhao S; Dai C; Xie D; Zhu Y; Wu C; Zhao D; Chen C;
    Am J Surg Pathol; 2022 Dec; 46(12):1633-1641. PubMed ID: 36224092
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical significance of thyroid transcription factor-1 in advanced lung adenocarcinoma under epidermal growth factor receptor tyrosine kinase inhibitor treatment.
    Chung KP; Huang YT; Chang YL; Yu CJ; Yang CH; Chang YC; Shih JY; Yang PC
    Chest; 2012 Feb; 141(2):420-428. PubMed ID: 21799026
    [TBL] [Abstract][Full Text] [Related]  

  • 10. SRGN-Triggered Aggressive and Immunosuppressive Phenotype in a Subset of TTF-1-Negative Lung Adenocarcinomas.
    Tanaka I; Dayde D; Tai MC; Mori H; Solis LM; Tripathi SC; Fahrmann JF; Unver N; Parhy G; Jain R; Parra ER; Murakami Y; Aguilar-Bonavides C; Mino B; Celiktas M; Dhillon D; Casabar JP; Nakatochi M; Stingo F; Baladandayuthapani V; Wang H; Katayama H; Dennison JB; Lorenzi PL; Do KA; Fujimoto J; Behrens C; Ostrin EJ; Rodriguez-Canales J; Hase T; Fukui T; Kajino T; Kato S; Yatabe Y; Hosoda W; Kawaguchi K; Yokoi K; Chen-Yoshikawa TF; Hasegawa Y; Gazdar AF; Wistuba II; Hanash S; Taguchi A
    J Natl Cancer Inst; 2022 Feb; 114(2):290-301. PubMed ID: 34524427
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic significance of thyroid transcription factor-1 expression in both early-stage conventional adenocarcinoma and bronchioloalveolar carcinoma of the lung.
    Saad RS; Liu YL; Han H; Landreneau RJ; Silverman JF
    Hum Pathol; 2004 Jan; 35(1):3-7. PubMed ID: 14745718
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Architectural Grade Combined With Spread Through Air Spaces (STAS) Predicts Recurrence and is Suitable for Stratifying Patients Who Might Be Eligible for Lung Sparing Surgery for Stage I Adenocarcinomas.
    Zombori T; Sejben A; Tiszlavicz L; Cserni G; Pálföldi R; Csada E; Furák J
    Pathol Oncol Res; 2020 Oct; 26(4):2451-2458. PubMed ID: 32564261
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comprehensive Study of Surgical Treated Lung Adenocarcinoma with Ground Glass Nodule Component.
    Xu Y; Zheng M; Wang N; Wang R
    Med Sci Monit; 2019 Nov; 25():8492-8498. PubMed ID: 31710020
    [TBL] [Abstract][Full Text] [Related]  

  • 14. BRMS1 Expression in Surgically Resected Lung Adenocarcinoma Predicts Future Metastases and Is Associated with a Poor Prognosis.
    Bucciarelli PR; Tan KS; Chudgar NP; Brandt W; Montecalvo J; Eguchi T; Liu Y; Aly R; Travis WD; Adusumilli PS; Jones DR
    J Thorac Oncol; 2018 Jan; 13(1):73-84. PubMed ID: 29097253
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Unique metastasis-associated lncRNA signature optimizes prediction of tumor relapse in lung adenocarcinoma.
    Zhang X; Han J; Du L; Li X; Hao J; Wang L; Zheng G; Duan W; Xie Y; Zhao Y; Zhang X; Zou M; Wang C
    Thorac Cancer; 2020 Mar; 11(3):728-737. PubMed ID: 31994347
    [TBL] [Abstract][Full Text] [Related]  

  • 16. EGFR and TTF-1 gene amplification in surgically resected lung adenocarcinomas: clinicopathologic significance and effect on response to EGFR-tyrosine kinase inhibitors in recurred cases.
    Lee JS; Kim HR; Lee CY; Shin M; Shim HS
    Ann Surg Oncol; 2013 Sep; 20(9):3015-22. PubMed ID: 23525704
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Thyroid transcription factor-1 expression prevalence and its clinical implications in non-small cell lung cancer: a high-throughput tissue microarray and immunohistochemistry study.
    Tan D; Li Q; Deeb G; Ramnath N; Slocum HK; Brooks J; Cheney R; Wiseman S; Anderson T; Loewen G
    Hum Pathol; 2003 Jun; 34(6):597-604. PubMed ID: 12827614
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Absence of thyroid transcription factor-1 expression is associated with poor survival in patients with advanced pulmonary adenocarcinoma treated with pemetrexed-based chemotherapy.
    Doherty MK; O'Connor E; Hannon D; O'Reilly A; Yen D; Redmond M; Grogan LM; Hennessy BT; Breathnach OS; Morris PG
    Ir J Med Sci; 2019 Feb; 188(1):69-74. PubMed ID: 29948461
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Expression and clinical significance of the thyroid transcription factor 1 in Xuanwei lung adenocarcinoma].
    Zu Y; Wang X; Liu X; Chen Y; Li C; Shang X; Xie Y; Zhao H; Wang J
    Zhongguo Fei Ai Za Zhi; 2013 Mar; 16(3):131-7. PubMed ID: 23514941
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Molecular genetic alterations in thyroid transcription factor 1-negative lung adenocarcinoma in cytology specimens: A subset with aggressive behavior and a poor prognosis.
    Rodriguez EF; VandenBussche CJ; Chowsilpa S; Maleki Z
    Cancer Cytopathol; 2018 Oct; 126(10):853-859. PubMed ID: 30199148
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.